Project description
Personalised medicine for coronary heart disease comes of age
Personalised medicine (tailoring prevention or intervention to individual patients' medical histories, conditions and circumstances) seems like a no-brainer. Every person is unique and has a specific health profile, a complicated combination of heredity, environment and lifestyle. Although physicians and scientists have been working for years toward personalised medicine, only recently has it become a real possibility, with advances in fields like genomics, data and informatics, and wearable technology. Working to prevent morbidity and mortality associated with coronary heart disease (CHD), the EU-funded CoroPrevention project is developing a personalised secondary prevention programme for patients with established CHD. The health, economic and social benefits of the methods will be rigorously evaluated along with the health economics, to improve treatment guidelines for the benefit of patients and healthcare systems.
Objective
European Coronary Heart Disease (CHD) burden is unsustainable. Better risk stratification tools and personalized care of patients are needed for reducing morbidity and mortality of CHD and the associated economic burden. To this end we have planned to shape and implement a personalized secondary prevention program for patients with established CHD. This precision strategy will be tested in a prospective trial, the CoroPrevention Trial, a central element of our proposal. We aim to significantly reduce the numbers of coronary events by using outcome risk- and patient characteristics- guided prevention in CHD patients.
1. Prospectively evaluate clinical utility of personalized prevention in CHD
2. Evaluate health economic and social benefits of the personalized prevention in CHD
3. Discover predictive markers of drug treatment response in CHD
4. Improve current ESC guidelines based on RCT validated clinical data
5. Disseminate the refined prevention program to the attention of practitioners, patients, health care payers and policy makers
This program will establish a new economically sustainable personalized treatment practice applicable throughout Europe particularly to those regions where CHD prevention needs upgrading. The used protocols and technologies will carefully assessed by NICE using their standard evaluation methods that will allow independent expert opinions for different European authorities and decision makers. These opinion statements will further be supported by full Health Economics analyses of CoroPrevention Trial.
Fields of science
Keywords
Programme(s)
Topic(s)
Funding Scheme
IA - Innovation actionCoordinator
33100 Tampere
Finland
See on map
Participants (25)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
33520 Tampere
See on map
06903 Biot Sophia Antipolis
See on map
M1 4BT Manchester
See on map
3500 Hasselt
See on map
90014 Oulu
See on map
10117 Berlin
See on map
02130 Espoo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
00029 Helsinki
See on map
Participation ended
31-007 Krakow
See on map
69117 Heidelberg
See on map
115 27 Athina
See on map
16132 Genova
See on map
1649-028 Lisboa
See on map
28029 Madrid
See on map
S10 2TN Sheffield
See on map
75654 Paris
See on map
02150 Espoo
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
86156 Ausburg
See on map
1860 Meise
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
37500 Lempaala
See on map
37500 LEMPAALA
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
01 813 WARSZAWA
See on map
1050 Riga
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
86156 Augsburg
See on map
1649-028 LISBOA
See on map